SHLP6

In cell culture models, SHLP6 induces apoptosis in multiple cell lines — the defining finding from the 2016 Cobb characterization. This is the most consistently documented effect across all SHLP6 literature: every review and subsequent paper that mentions SHLP6 cites this pro-apoptotic activity as its distinguishing characteristic. The specific cellular machinery activated (which caspase pathway, which Bcl-2 family members, which mitochondrial events) has been modeled in silico but not yet characterized in wet lab experiments. Grade B for the broad finding (apoptosis induction in cell culture); Grade D for the specific mechanistic pathway (in silico only).

The hypothesis that SHLP6 kills cancer cells while sparing normal cells is the most clinically interesting claim about this compound. If true, it would position SHLP6 alongside FOXO4-DRI in the category of compounds that selectively eliminate aberrant cells — but with a fundamentally different mechanism (SHLP6 targets cellular damage signals rather than senescent cell survival; it appears to work through apoptotic pathway activation rather than p53 release). The evidence for selectivity: (1) the biological logic is sound — cancer cells and pre-cancerous cells have altered Bcl-2/Bax ratios and different apoptotic thresholds; (2) the Frontiers 2025 paper asserts dual functionality; (3) zebrafish neuroprotection suggests cytoprotection in non-cancer contexts. Direct experimental comparison of SHLP6's effects in matched cancer vs normal cell lines has not been published. Grade C: plausible hypothesis with supporting indirect evidence; not directly confirmed.

The Frontiers 2025 paper showed SHLP6 protected zebrafish larvae from copper-induced neurotoxicity through NLRP3 and Cav1 modulation. AChE (acetylcholinesterase) activity, a marker of cholinergic neuron health, improved in a dose-dependent manner after SHLP6 treatment in copper-exposed larvae. This neuroprotective finding was not predicted from the 2016 apoptosis data and represents the most unexpected dimension of SHLP6's biology — a pro-apoptotic compound that also protects neurons. This is where the dual-function hypothesis becomes necessary to explain the literature: SHLP6 may behave differently in stressed-but-recoverable neurons (where it provides cytoprotection by modulating inflammation and oxidative stress) than in cancer cells (where it drives apoptosis). Grade C: zebrafish model; independent from Cohen group; published 2025; not yet replicated in mammalian neuronal models.

The hypothesis that SHLP6 functions as a natural cancer surveillance mechanism — eliminating pre-cancerous cells through mitochondria-encoded apoptotic signaling — is the most compelling theoretical framework for the compound. The positive natural selection signatures (Barker & Bhatt 2023) suggest this function is evolutionarily important. The pro-apoptotic activity in cell culture is consistent with it. The tissue expression in liver and kidney — organs with high cancer incidence and high metabolic stress — is circumstantially consistent. But no experiment has directly demonstrated SHLP6 preventing cancer development through selective elimination of pre-cancerous cells in any model system. Grade X: compelling hypothesis; indirect supporting evidence; not experimentally confirmed.

SHLP6: approximately 20 amino acids. Published sequence: MLDQDIPMVQPLLKVRLEND. Encoded within the MT-RNR2 gene (mitochondrial 16S rRNA) at a different sORF position from SHLP2 and the other family members. Like the other SHLPs, SHLP6 is a secreted peptide — produced inside cells and detectable in extracellular contexts. Expression documented in liver and kidney in mouse tissue distribution studies (Cobb 2016) — different from SHLP2's expression in liver, kidney, and muscle, suggesting tissue-specific roles. Molecular weight: approximately 2,200-2,400 Da depending on posttranslational modifications.

SEQUENCE AND FAMILY DISAMBIGUATION — VERIFY IDENTITY RIGOROUSLY

SHLP6 sequence: MLDQDIPMVQPLLKVRLEND. This is distinct from all other SHLPs. Given SHLP6's pro-apoptotic effects, receiving the wrong SHLP from a vendor is not merely a matter of getting a less effective compound — it means receiving a compound with a completely different biological profile. A batch of SHLP2 or SHLP3 sold as SHLP6 would be cytoprotective rather than pro-apoptotic. A batch of SHLP6 sold as SHLP2 could cause unexpected cell death in a user expecting cytoprotection. Mass spectrometry identity confirmation at the expected molecular weight is absolutely non-negotiable for any SHLP. This applies to all SHLPs but has the highest stakes for SHLP6.

SHLP6: lyophilized powder reconstituted with bacteriostatic water. Standard storage: -20C for long-term; 2-8C after reconstitution; use within 30 days. Mass spectrometry confirming ~2,200-2,400 Da is the identity check — the exact MW will depend on the specific synthesis and any modifications. HPLC purity 98%+. SHLP6 is among the least commercially available of all SHLPs due to its unusual biological profile and small community. Very few vendors carry it; batch quality verification is correspondingly important.

The Barker & Bhatt (PNAS, 2023) evolutionary analysis deserves attention as independent evidence of biological importance. By examining synonymous codon bias and other signatures of selection pressure across vertebrate lineages, these authors found that SHLP6 (and Humanin) show evidence of positive natural selection — meaning natural selection has acted to preserve specific amino acid sequences in SHLP6 across millions of years of evolution. This is meaningful: randomly maintained pseudogene sequences show no such selection signature. The fact that SHLP6 has been selected for, alongside Humanin, suggests both peptides perform important biological functions. The selection analysis is from an independent group (not the Cohen lab) and provides molecular evolutionary evidence that SHLP6 matters — even if the specific mechanism remains incompletely characterized.

The foundational finding from Cobb et al. (Aging, 2016): SHLP6 treatment caused significant apoptosis in NIT-1 pancreatic beta cells and 22RV1 prostate epithelial cells in culture. This was not marginal — the effect was distinct from all other SHLPs and clearly pro-apoptotic rather than cytoprotective. The paper's cell viability data placed SHLP6 firmly in the 'induces cell death' category. This finding has been repeatedly cited in subsequent reviews (JCI 2022, Molecular Medicine Reports 2025) as established. Grade B for the apoptosis finding: published in peer-reviewed journal; internally consistent; multiple cell types; Cohen group primary — but the original finding has been cited rather than independently replicated in wet lab experiments by other groups.

The 2025 Frontiers paper on SHLP6 in copper-induced neurodegeneration articulates the dual functionality hypothesis: SHLP6 exhibits 'pro-apoptotic activity in cancer cells and cytoprotective effects in normal cells, making it suitable for targeted therapies.' This framing would explain why SHLP6 exists at all — if it killed all cells indiscriminately, it would be toxic to the organism rather than beneficial. If it specifically kills dysfunctional cells while sparing healthy ones, it would be an elegant quality control mechanism. The mechanistic basis for this selectivity is proposed but not directly demonstrated in a clean controlled experiment: stressed, damaged, or malignantly transformed cells may express different apoptotic protein profiles (higher Bax, altered Bcl-2/Bax ratio) that make them preferentially sensitive to SHLP6's pro-apoptotic signaling. Grade C: hypothesis with mechanistic plausibility; supporting in silico evidence; not yet confirmed in direct comparative in vitro experiment or animal model.

The 2025 ScienceDirect in silico study performed molecular docking of SHLP6 against multiple apoptotic proteins. Key predicted binding affinities: Caspase 8 (-77.6 ± 2.9 kcal/mol), cytochrome c (-53.2 ± 8.7 kcal/mol), DRP1 (-47.7 ± 1.9 kcal/mol — DRP1 promotes mitochondrial fission and is associated with apoptosis), Bcl-2 (39.2 ± 15.3 kcal/mol), Bax (43.6 ± 7.7 kcal/mol). The Caspase 8 binding would activate extrinsic apoptosis (death receptor pathway); cytochrome c binding would affect intrinsic apoptosis (mitochondrial pathway); DRP1 interaction would affect mitochondrial dynamics. The same study showed SIRT1 and IGF-1 binding affinities, suggesting potential interactions with longevity and metabolic pathways beyond pure apoptosis. Grade D: all in silico molecular docking — computationally predicted, not experimentally confirmed. Molecular docking scores are starting hypotheses for wet lab validation, not established mechanisms.

The 2025 Frontiers paper studied SHLP6 in a copper-induced oxidative stress model using zebrafish larvae — a model for neurodegeneration research. SHLP6 modulated NLRP3 inflammasome activity and Cav1 (caveolin-1) expression, improving acetylcholinesterase (AChE) levels in a concentration-dependent manner following copper exposure. This is a genuinely surprising finding for a compound characterized as pro-apoptotic: it appears to have neuroprotective properties in the context of copper-induced oxidative stress, consistent with the dual-function hypothesis (cytoprotective in stressed-but-not-malignant cells). The zebrafish model, while not a mammalian system, is a legitimate in vivo model for neurotoxicity research. Grade C: in vivo zebrafish model; independent from Cobb 2016; Frontiers journal; mechanistically interesting but early.

The most compelling theoretical framework for SHLP6's existence: mitochondrial-encoded apoptotic signaling for cellular quality control. Mitochondria are exquisitely sensitive to cellular damage — they accumulate mutations, produce more ROS under stress, and can detect when a cell has crossed critical damage thresholds. An MDP that signals 'this cell should die' would serve a quality control function for the organism as a whole, eliminating cells before they become cancerous or chronically dysfunctional. This would explain why SHLP6 shows positive natural selection signatures (Barker & Bhatt 2023) — an organism whose SHLP6 doesn't work efficiently might accumulate more damaged cells and develop cancer at higher rates. This hypothesis is internally consistent and biologically elegant. It is not yet experimentally confirmed as SHLP6's primary biological role.

SHLP6 pharmacokinetics are completely uncharacterized. No published PK study in any species. Plasma half-life, tissue distribution, CNS penetration, metabolite profile — all unknown. Given its mitochondrial-encoded nature, SHLP6 is likely a secreted peptide with systemic bioavailability, but the specific PK profile cannot be inferred from molecular weight alone. Community protocols mirror SHLP2 dosing by default — which is itself unvalidated.

SHLP6: lyophilized powder reconstituted with bacteriostatic water. Solution is clear to slightly opalescent. Refrigerate at 2-8C; use within 30 days. Mass spectrometry at expected MW (~2,200-2,400 Da) is the identity check — and given the stakes of SHLP family mix-ups (see Section 2.4), this verification is particularly important. HPLC purity 98%+.

Community use of SHLP6 is so limited that 'protocol' overstates what exists. The community practice is:

• 0.5-1 mg SubQ, weekly or biweekly
• Usually run alone or as part of a senolytic-adjacent stack (with FOXO4-DRI)
• Short cycles (2-4 weeks) with extended breaks
• Users are almost universally aware of the pro-apoptotic mechanism and have made a specific choice to explore it

There is no evidence-based dose for SHLP6. The dose being used by community members may be far below any pharmacologically active threshold, or may be within a range that produces apoptotic signaling in some tissues. There is no way to know.

Some community users conceptualize SHLP6 as a natural senolytic — a compound that eliminates damaged cells, analogous to FOXO4-DRI. This framing has intuitive appeal given the pro-apoptotic mechanism. The key difference: FOXO4-DRI's selectivity is mechanistically grounded — senescent cells overexpress FOXO4 at 10-20x the level of healthy cells, providing a documented pharmacological window. SHLP6's proposed selectivity for cancer/damaged cells vs normal cells is a hypothesis, not a confirmed mechanism. Running SHLP6 as a 'natural senolytic' rests on unconfirmed selectivity assumptions.

SHLP6 has no published safety study in any species. No pharmacological assessment of off-target effects. No toxicology data. The pro-apoptotic mechanism creates a specific concern not present for any other compound in this book: if SHLP6 kills cells at pharmacologically relevant concentrations and does so without the proposed selectivity for cancer/damaged cells, it could cause inappropriate apoptosis in normal tissues. The community's extremely conservative doses (0.5-1 mg weekly) may be protective against this simply by being below any pharmacologically active concentration — but this is not confirmed.

SHLP6 AND CANCER — THE QUESTION THAT CANNOT BE ANSWERED BY CURRENT EVIDENCE

Every other compound in this book carries an 'active malignancy — active malignancy caution' or 'active malignancy contraindication' based on pro-survival, angiogenic, or IGFBP-3 neutralizing mechanisms that could theoretically support tumor cell survival. SHLP6 is the opposite: its proposed mechanism is pro-apoptotic in cancer cells. This creates the possibility that SHLP6 could be beneficial rather than harmful in cancer contexts — if the dual-function hypothesis is correct. However: (1) the dual-function hypothesis is not confirmed; (2) if SHLP6 is not selective for cancer cells, it could cause inappropriate apoptosis in normal tissues in cancer patients who may already be immunocompromised or have reduced tissue reserves; (3) the interaction between SHLP6 and cancer treatment drugs (chemotherapy, immunotherapy) is completely unknown. The honest answer: SHLP6 near active malignancy is a question that cannot be responsibly answered by the available evidence. Anyone with cancer considering SHLP6 must discuss with their oncologist — not because we know it's harmful, but because we know nothing about its behavior in that context.

• Healthy tissue apoptosis risk: the most relevant theoretical concern. If SHLP6 is not selective for damaged/cancer cells, standard doses could trigger apoptosis in normal cells. Without dose-response data in any living system, this risk is unquantifiable.
• Pregnancy: absolute contraindication — pro-apoptotic compounds have no place in the context of active fetal development.
• Children and adolescents: absolute contraindication — rapidly dividing healthy cells are most vulnerable to apoptotic signals.
• Combination with FOXO4-DRI: both are pro-apoptotic via different mechanisms. Running both simultaneously is a double pro-apoptotic load without any data on combined safety. Conservative approach: run one at a time with full cycle breaks.

Not FDA-approved. Not PCAC-reviewed. Not WADA-listed. Research chemical only. Not a controlled substance. The community using SHLP6 is, by any reasonable standard, conducting unmonitored first-in-human pharmacological experimentation with a compound whose primary characterized biological activity is inducing cell death.

Both SHLP6 and FOXO4-DRI are pro-apoptotic. FOXO4-DRI kills senescent cells via p53 release from FOXO4 sequestration — a well-characterized selectivity mechanism. SHLP6's selectivity for damaged/cancer cells vs normal cells is hypothetical. Running both simultaneously is not recommended: dual pro-apoptotic load without established selectivity confirmation for SHLP6, and without any data on how the two mechanisms interact. Sequential use — FOXO4-DRI for senescent cell clearance, then SHLP6 separately — reduces the combinatorial uncertainty.

Humanin is anti-apoptotic (Bax neutralization, GP130/STAT3 pro-survival). SHLP6 is pro-apoptotic. These are mechanistically opposing compounds. Running them simultaneously is pharmacologically counterproductive — each partially negates the other's primary mechanism. Do not combine.

SHLP2 is cytoprotective and insulin-sensitizing. SHLP6 is pro-apoptotic. Their mechanisms are largely opposing at the cell death/survival decision level. Combining them makes little pharmacological sense given current understanding of their mechanisms.

Given SHLP6's unusual mechanism and very early evidence base, the most appropriate community use context is as a standalone compound in short, isolated cycles — specifically to explore its pro-apoptotic effects without confounding influences from other compounds that could obscure its actual biological activity. Users who want to contribute meaningful self-experimentation data should: establish a clear baseline (health markers, blood panels, subjective wellbeing); run SHLP6 alone for 2-4 weeks at conservative dose; assess changes at cycle end; allow full washout before adding any other compound. This approach provides the cleanest possible self-observation, which is the only available data collection method for a compound with no human trial.

The SHLP6 user profile is unlike any other compound in this book. The typical user is not primarily seeking anti-aging benefits or performance enhancement — they are specifically interested in the pro-apoptotic mechanism and its potential implications for cellular quality control or cancer biology. This requires a level of mechanistic sophistication and risk tolerance that distinguishes SHLP6 from the broader community context of most compounds here. An appropriate SHLP6 user: deeply understands the pro-apoptotic mechanism; has read the primary literature (Cobb 2016, Frontiers 2025, Barker & Bhatt 2023); accepts that the dual-function hypothesis is unconfirmed; uses conservative doses; runs it as a standalone compound; monitors carefully; and ideally has some ongoing clinical relationship that allows discussion of unusual self-experimentation.

• Treating SHLP6 like a 'natural senolytic' without confirmed selectivity: FOXO4-DRI has a mechanistically confirmed selectivity window. SHLP6's selectivity is a hypothesis. Using SHLP6 as a casual senolytic assumes selectivity that has not been established.
• Combining with Humanin, SHLP2, or other cytoprotective MDPs simultaneously: opposing mechanisms. The compounds partially cancel each other out. Run them in sequence, not simultaneously.
• Using SHLP6 without mass spec identity confirmation: the stakes of SHLP family mix-ups are highest for SHLP6 — receiving a cytoprotective SHLP when you think you have a pro-apoptotic one (or vice versa) would fundamentally alter the intended protocol. Verify.
• Assuming absence of adverse effects = safety: the very small community using SHLP6 has not reported serious adverse effects. This does not constitute a safety database. SHLP6's community is too small and too new for absence-of-reports to mean much.

Short cycles are mandatory by conservative principle: 2-4 weeks on, 8-12 weeks off. The pro-apoptotic mechanism argues against extended continuous use — even if SHLP6 is selective for damaged cells, continuous apoptotic signaling over months creates cumulative uncertainty. The extended breaks allow tissue assessment and full washout before the next cycle.

Any user of SHLP6 should establish baseline blood panels (CBC, CMP, LDH, liver enzymes) before starting a cycle and repeat at cycle end. LDH elevation can be a marker of tissue apoptosis. Liver enzymes are relevant given SHLP6's liver expression. CBC changes could reflect effects on rapidly dividing blood cell populations. None of these are SHLP6-specific biomarkers — but they provide the most accessible indirect signal that something is happening at the cellular level.

Cobb LJ, Lee C, Xiao J, et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 8(4):796-809. PMC4925829. [Discovery paper for all SHLPs including SHLP6. Pro-apoptotic effect of SHLP6 in NIT-1 and 22RV1 cell lines established. Tissue distribution including liver and kidney. Cohen group USC.]

Barker A, Bhatt DL. (PNAS, 2023). Evidence of natural selection in the mitochondrial-derived peptides humanin and SHLP6. PMID 37644144. [INDEPENDENT of Cohen group. Synonymous codon bias analysis across vertebrate lineages shows positive natural selection acting on Humanin and SHLP6 sequences — implying functional importance maintained over evolutionary time. Key independent evidence that SHLP6 matters biologically.]

Frontiers in Molecular Neuroscience. (2025). SHLP6: a novel NLRP3 and Cav1 modulating agent in Cu-induced oxidative stress and neurodegeneration. doi:10.3389/fnmol.2025.1553308. [INDEPENDENT. Zebrafish model. SHLP6 modulates NLRP3 inflammasome and Cav1. AChE improvement dose-dependent. Neuroprotective in copper-induced neurotoxicity. Dual-function hypothesis articulated: pro-apoptotic in cancer, cytoprotective in normal cells.]

Kannan HT, Umapathy S, Pan I. (Computers in Biology and Medicine, 2025). In-silico modeling of SHLP6: A novel mitochondrial peptide controlling neurodegeneration and cellular aging. doi:10.1016/j.compbiomed.2025.111054. PMID 40915070. [INDEPENDENT Indian academic group. 3D structure prediction, Ramachandran plot analysis, molecular docking with Caspase 8, Bcl-2, Bax, Cyt-C, DRP1, SIRT1, IGF-1, INSR. Grade D — in silico only, not wet lab confirmed.]

JCI (Journal of Clinical Investigation). (2022). Mitochondria-derived peptides in aging and healthspan. doi:10.1172/JCI158449. [Authoritative review explicitly stating 'unlike these cytoprotective SHLPs, SHLP6 was shown to induce apoptosis in multiple cell lines.' Positions SHLP6 as the pro-apoptotic outlier in the family.]

Molecular Medicine Reports. (2025). 31:127. Review of MDPs in cardiovascular disease. [Confirms 'SHLP6 promotes apoptosis' in the context of MDP family differentiation.]

MDP

Primary Function

Evidence Base

SHLP6 Relationship

WADA

Humanin

Cytoprotective — anti-apoptotic

B (24 years, multi-lab)

Opposing mechanism (anti-apoptotic vs pro-apoptotic); do not combine

Not listed

MOTS-c

Metabolic — AMPK/exercise mimicry

B (multi-lab)

Different mechanism; orthogonal; can sequence but not simultaneously

S4.4 banned

SHLP2

Metabolic/cytoprotective — CXCR7/POMC

B-C (8 years, partial independent)

Cytoprotective; opposing survival signaling to SHLP6; do not combine

Not listed

SHLP6

Pro-apoptotic — cellular quality control (hypothesis)

C-D (9 years; limited)

The outlier; do not combine with cytoprotective MDPs

Not listed

SS-31

Structural — cardiolipin/ETC

A-B (clinical trials)

Different compartment (IMM structural vs apoptotic); can theoretically sequence

Not listed

• 'Pro-apoptotic in cancer cells' = proven anti-cancer therapeutic: the dual-function hypothesis that SHLP6 specifically targets cancer cells is unconfirmed. The pro-apoptotic finding is in general cell culture, not in a cancer-selective comparison.
• Evolutionary selection = therapeutic safety: positive natural selection means SHLP6 performs an important biological function. It does not mean exogenous SHLP6 supplementation is safe at community doses or any dose.
• SHLP6 is like FOXO4-DRI but natural: FOXO4-DRI has confirmed selectivity (10-20x higher FOXO4 in senescent cells, well-characterized). SHLP6 selectivity is a hypothesis. The 'natural' origin doesn't mitigate the uncertainty.
• Zebrafish neuroprotection proves SHLP6 is safe in normal cells: zebrafish results in copper-toxicity models cannot be extrapolated to human safety in normal tissue. Different species, different model, different endpoints.

— End of SHLP6 —

THE PEPTIDE BIBLE | SHLP6 | For Research & Educational Purposes Only